Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Position Lowered by Speece Thorson Capital Group Inc.

Speece Thorson Capital Group Inc. trimmed its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 1.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 178,761 shares of the medical equipment provider's stock after selling 3,039 shares during the period. Zimmer Biomet accounts for approximately 4.2% of Speece Thorson Capital Group Inc.'s holdings, making the stock its 2nd largest position. Speece Thorson Capital Group Inc. owned about 0.09% of Zimmer Biomet worth $20,232,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC purchased a new stake in Zimmer Biomet in the 4th quarter worth $204,000. Proficio Capital Partners LLC purchased a new stake in Zimmer Biomet in the 4th quarter worth $55,000. Raymond James Financial Inc. purchased a new stake in Zimmer Biomet in the 4th quarter worth $21,234,000. AGF Management Ltd. purchased a new stake in Zimmer Biomet in the 4th quarter worth $590,000. Finally, EverSource Wealth Advisors LLC increased its stake in Zimmer Biomet by 143.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,118 shares of the medical equipment provider's stock worth $224,000 after buying an additional 1,247 shares in the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ZBH. Roth Capital upgraded Zimmer Biomet from a "neutral" rating to a "buy" rating and set a $135.00 price target for the company in a research note on Tuesday. Truist Financial set a $101.00 price objective on shares of Zimmer Biomet in a report on Tuesday, May 6th. Robert W. Baird dropped their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Canaccord Genuity Group dropped their price objective on shares of Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating for the company in a report on Monday, May 12th. Finally, BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Zimmer Biomet presently has an average rating of "Hold" and an average target price of $111.39.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the firm's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the sale, the insider owned 20,424 shares of the company's stock, valued at $1,940,280. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.39% of the stock is currently owned by insiders.

Zimmer Biomet Trading Up 0.2%

Shares of NYSE:ZBH traded up $0.17 during trading on Wednesday, reaching $94.20. The company's stock had a trading volume of 1,467,382 shares, compared to its average volume of 1,831,907. The company has a current ratio of 2.44, a quick ratio of 1.46 and a debt-to-equity ratio of 0.53. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.22 and a 12 month high of $116.71. The firm's 50 day simple moving average is $93.31 and its two-hundred day simple moving average is $101.13. The stock has a market capitalization of $18.64 billion, a PE ratio of 20.84, a price-to-earnings-growth ratio of 2.17 and a beta of 0.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The business had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The firm's quarterly revenue was up 1.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.94 earnings per share. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.02%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's payout ratio is currently 21.24%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.